Navigation Links
Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment
Date:10/22/2008

COPENHAGEN, October 22 /PRNewswire-FirstCall/ -- Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX(R). For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment.

Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX(R), the company's tablet-based vaccine against grass pollen allergy. The clinical study documents that the effect of GRAZAX(R) persists following completion of the recommended three-year treatment regimen. Furthermore, blood samples from patients show a persistent, positive effect on the immune system indicating a lasting tolerance to grass pollen.

During the first year after completion of treatment, GRAZAX(R) continues to provide statistically significant reductions in both hay fever symptoms and the use of symptom-relieving medication.

In the follow-up year, hay fever symptoms were reduced by 31% while the use of symptom-relieving medication was reduced by 52%. The reduction of symptoms and use of medication is measured as median values relative to a control group in which patients had unrestricted access to symptom-relieving medication.

The patients in the study have adhered to the recommended three-year GRAZAX(R) treatment regimen and completed treatment in the autumn of 2007. The above-mentioned results cover the 2008 pollen season, the first season in which the patients did not receive active treatment with GRAZAX(R).

The fourth-year results represent a major breakthrough, since ALK is the first company ever to document a persistent disease modifying vaccination effect of a tablet-based allergy vaccine. Patients cannot obtain such a persistent vaccination effect with traditional symptom-relieving allergy medication.
ALK-Abelló A/S - Company release No 14/2008 - October 22, 2008

ALK-Abelló A/S

Jens Bager

President and CEO

For further information please contact:

Jens Bager, President and CEO, tel. +45-4575-7576

Investor Relations: Per Plotnikof, tel +45-4574-7527, mobile +45-2261-2525

Press: Jacob Frische, tel +45-4574-7551, mobile +45-2224-7551


'/>"/>
SOURCE ALK-Abello A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Phase III Trial Finds Pharmaxis Bronchitol Effective
3. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
4. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
5. New nanoparticle vaccine is more effective but less expensive
6. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions ... scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):